Advertisement

Health Economics in the Genomic Age

  • Thomas D. Szucs
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 166)

Abstract

Health economics has experienced a substantial rise within the healthcare industry over the past few years. Several disciplines have developed new techniques to evaluate the economic impact of pharmaceuticals in clinical care. Clinicians, pharmacists, economists, epidemiologists, and operations researchers have contributed to this field. Given the economic reality that resources are limited and needs and expectations are not infinite, medical economists try to find solutions on how these resources can be allocated optimally, to maximize the production of health or what society perceives as health. Health economists differentiate allocation efficiency and production efficiency. From the perspective of a health insurance plan allocation efficiency is reached when those drug classes or clinical programs are covered that will produce most health per expenditure. This requires a common monetary metric of health gains across the broad spectrum of diseases, conditions, and health outcomes. Once it is decided to cover a specific treatment or clinical program, economists try to identify the most cost-effective product within a class of comparable choices using cost-effectiveness and cost-utility analyses. Both allocation and production efficiency are two critically important concepts for the economic success of biotech products. This article will provide a rationale why health economics is critically important for the future of healthcare and explains fundamental economic tools for evaluating products and services with special emphasis on gene-derived technologies.

Keywords

National Health Service Direct Medical Cost Hospital Sector Pharmacoeconomic Study Private Insurer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Harris A, Buxton M, O’Brien B, Ruttem F, Drummond M (2001) Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries. Expert Rev Pharmacoeconom Outcomes Res 1: 7–12Google Scholar
  2. 2.
    Birkett DJ, Mitchell AS, McManus P (2001) A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff (Millwood) 20:104–114CrossRefGoogle Scholar
  3. 3.
    Rice T (1998) The economics of health reconsidered. Health Administration Press, ChicagoGoogle Scholar
  4. 4.
    PausJenssen AM, Singer PA, Detsky AS (2003) Ontario’s formulary committee. How recommendations are made. PharmacoEconomics 21:285–294PubMedGoogle Scholar
  5. 5.
    Ess S, Schneeweiss S, Szucs T (2003) European healthcare policies for controlling drug expenditure. PharmacoEconomics 21:89–103PubMedGoogle Scholar
  6. 6.
    Institute of Medicine (1997) Managing managed care: quality improvement in behavioral health. National Academy Press, WashingtonGoogle Scholar
  7. 7.
    Navarro RP (1998) Exporting managed care: importing quality lessons. Manag Care Interface 11:61–62Google Scholar
  8. 8.
    Feachem RG, Sekhri NK, White KL (2002) Getting more for their dollar: a comparison of the NHS with California’s Kaiser Permanente. BMJ 324:135–141PubMedGoogle Scholar
  9. 9.
    Shortell SM, Kaluzny AD (1997) Essentials of health care management. Delmar, AlbanyGoogle Scholar
  10. 10.
    Bleecker GC (1993) Reimbursement and pharmacoeconomic perspectives in biotechnology. Am J Hosp Pharm 50:S27–S30PubMedGoogle Scholar
  11. 11.
    Weatherly H, Drummond M, Smith D (2002) Using evidence in the development of local health policies. Some evidence from the United Kingdom. Int J Technol Assess Health Care 18:771–781PubMedGoogle Scholar
  12. 12.
    Drummond MF, O’Brien B, Stoddart GL, Torrance GW (1997) Methods for the evaluation of health care programs, 2nd edn. Oxford Medical Publications, OxfordGoogle Scholar
  13. 13.
    Weinstein MC (1996) From cost-effectiveness ratios to resource allocation: where to draw the line? In: Sloan FA (ed) Valuing health care. Cambridge University Press, Cambridge, pp 77–97Google Scholar
  14. 14.
    Tengs T (2000) One thousand quality-of-life estimates. Med Care 38:592–637CrossRefGoogle Scholar
  15. 15.
    Harris A, Buxton M, O’Brien B, Rutten F, Drummond M (2003) Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries. http://www.future-drugs.com. Cited 1 Apr 2003Google Scholar
  16. 16.
    Hill SR, Mitchell AS, Henry DA (2000) Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 283:2116–2121PubMedCrossRefGoogle Scholar
  17. 17.
    Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New YorkGoogle Scholar
  18. 18.
    Lee RH (2000) Economics for healthcare managers. Health Administration Press, WashingtonGoogle Scholar
  19. 19.
    Robertson JA, Brody B, Buchanan A, Kahn J, McPerson E (2002) Pharmacogenetic challenges for the health care system. Health Aff (Millwood) 21:155–167CrossRefGoogle Scholar
  20. 20.
    Foot E, Bieber F, Kroll W, et al (2001) Impact of pharmacogenetics on health care and health economics. Int J Pharm Med 15:95–100CrossRefGoogle Scholar
  21. 21.
    Morgan S, Hurley J, Miller F, Giacomini M (2003) Predictive genetic tests and health system costs. Can Med Assoc J 168: 989–991Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Thomas D. Szucs
    • 1
  1. 1.Institute of Social and Preventive MedicineZurichSwitzerland

Personalised recommendations